

11 January 2010

IS Pharma plc ('IS Pharma')

IS Pharma granted exclusive license and supply rights for Aequasyl® (oxidised glycerol triester) in the UK

IS Pharma plc (LSE:ISPH), the international specialist pharmaceutical company, and Laboratoires Carilène S.A.S (Laboratoires Carilène), a privately owned French pharmaceutical group, announce the signing of an agreement granting IS Pharma the exclusive License and Supply rights for Aequasyl (oxidised glycerol triester) oral spray in the UK.

Aequasyl is an oral spray, indicated for the lubrication and protection of the oral mucosa in xerostomia dry mouth (xerostomia), a symptom common in cancer patients. The product is registered across Europe as a Medical Device.

Aequasyl is currently being successfully marketed in France and the US. Aequasyl is differentiated by the duration of time over which it reduces pain and inflammation caused by xerostomia. Launch in the UK is anticipated during Q2 2010.

Under the terms of the agreement IS Pharma has also acquired the option for exclusive rights to Aequasyl in Germany.

Tim Wright, CEO of IS Pharma said:

"Laboratoires Carilène has developed an excellent product in Aequasyl® with already proven sales success, we are delighted to become their UK partner.

This is a further step in the successful implementation of our strategy of building IS Pharma through the acquisition and growth of specialist hospital medicines; with a particular focus on growing profits and EPS. The licensing of a complementary oncology product such as Aequasyl® is another example of our continuing momentum.

As we enter the last quarter of the financial year this positive progress is being maintained, particularly driven by the launch of Variquel which in just six months has gained 25% share of the UK market. The Company is well positioned for sustained growth"

Stéphane Desjonqueres, President of Laboratoires Carilène said:

"We are delighted to sign this agreement with IS Pharma who have demonstrated their ability to grow products in the specialist hospital medicines market, and we see a strong synergy for Aequasyl with their current portfolio."

- Ends -

For further information, call:

IS Pharma plc

Tel: +44(0) 1244 625150

Tim Wright – CEO / Matthew Hall - CFO

Financial Dynamics Limited

Tel: +44(0) 20 7831 3113

Billy Clegg / Edward Westropp

Piper Jaffray Ltd

Tel: +44 (0) 20 3142 8700

Neil Mackison / Rupert Winckler

About Xerostomia

Xerostomia is caused by a lack of saliva which can cause damage to the condition of the mouth membrane. Xerostomia has been estimated to have a prevalence of between 22% and 26% in the general population but is a common problem in patients who have undergone head and neck radiotherapy, polymedicated elderly patients and those taking certain drug therapies such as anti-cholinergics. Xerostomia can also be a symptom of various systemic diseases such as autoimmune diseases (e.g. Sjogren syndrome), or in patients requiring palliative care. The condition can induce a marked deterioration of the quality of life of a patient causing extreme discomfort and active management is essential.

About Aequasyl

Aequasyl is a lubricating and protective oral spray composed predominantly of OGT. OGT has a lubricating effect on the oral mucosa, to which it adheres by forming a lipid film that protects it from mechanical trauma. The lipid protector and adhesive film limits water loss from oral tissues facilitating micro perfusion and promoting underlying cellular renewal, protects the inflamed oral mucous membrane from painful mechanical trauma and reduces the inflammatory process by impregnating the oral mucosa. Aequasyl has been shown to reduce the dryness of the oral mucosa in patients with decreased salivary function and to reduce the pain and inflammation caused by xerostomia.

About Laboratoires Carilène S.A.S

Laboratoires Carilène is a privately owned French pharmaceutical company founded in 1982 by Dr Stéphane Desjonquieres. Specialising in the Research and Development of Oxidised Glycerol Triester (OGT) products Laboratoires Carilène have had commercialised many OGT products in different therapeutic areas.

To find out more please go to: www.carilene.fr

Contact person Laboratoires Carilène:
Dr. Stéphane Desjonquieres - President
Tel: +33 (0)1 30 15 58 90
Email: stephane.desjonquieres@carilene.fr

About IS Pharma plc (LSE: ISPH)

IS Pharma (International Speciality Pharmaceuticals) is a fast growing, profitable business which develops, acquires and commercialises late-stage pharmaceuticals and medical devices, focusing in critical care, oncology and neurology. Based in the UK, IS Pharma commercialises its portfolio in the UK directly and internationally through a strong network of distributors.

To find out more please go to www.ispharma.plc.uk